Aplagon doses first patient in phase 2a trial of APAC with peripheral arterial occlusive disease/chronic limb threatening ischemia: Helsinki, Finland Saturday, March 14, 2026, 18: ...

THAN FOCUSING ON THE WINS AND LOSSES. A BRAND NEW WAY TO DO WHAT’S USUALLY AN INVASIVE AND COMPLEX PROCEDURE ENDED UP BONDING A FATHER AND SON IN A REALLY SPECIAL WAY. WESH 2 NEWS BREVARD COUNTY ...

Merit Medical Systems, Inc. MMSI is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid performance in 2025 and its continued spending ...

Aplagon is also planning for 2026 a Phase 2 clinical trial for arteriovenous fistula (AVF) maturation failure in Europe, following the successful completion of its Phase 1 AVF trial. The study ...

Peripheral artery disease (PAD) affects millions of Americans, yet access to timely, specialized care remains limited in many regions. The Rio Grande Valley, in particular, has historically faced a sc ...

BACKGROUND: Peripheral artery disease (PAD) and its severe form, chronic limb-threatening ischemia (CLTI), significantly impair blood flow to the lower extremities, affecting millions of adults ...

The peripheral vascular device market will rise from $10.4B in 2025 to $14.8B by 2032, driven by drug‑coated balloons, ...

A 65-year-old white woman presented with 9 months of intermittent “kaleidoscopic” visual disturbances and blurred vision upon ...

Dr. Hasan Rehman, an Interventional Cardiologist at Prairie Cardiovascular in O’Fallon, Illinois, specializes in the ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced that it has received CE Mark approval in the European Union for its Revello Vascular Covered Stent. With this approval, BD ...

The Revello™ Vascular Covered Stent is designed to combine the flexibility of a nitinol self-expanding stent with the radial ...